Yahoo
NasdaqGS - Nasdaq Real Time Price USD

MBX Biosciences, Inc. (MBX)

43.03 +1.44 (+3.46%)
As of June 18 at 4:00:01 PM EDT. Market Open.
Trade MBX on Coinbase
Chart Range Bar
Loading chart for MBX
  • Previous Close 41.59
  • Open 42.84
  • Bid 30.53 x 200
  • Ask 52.22 x 200
  • Day's Range 40.76 - 43.49
  • 52 Week Range 9.43 - 45.85
  • Volume 791,968
  • Avg. Volume 655,541
  • Market Cap (intraday) 2.048B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.17
  • Earnings Date (est.) Aug 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 69.09

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

mbxbio.com

63

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MBX
36.43%
S&P 500 (^GSPC)
9.57%

1-Year Return

MBX
318.58%
S&P 500 (^GSPC)
25.41%

3-Year Return

MBX
87.09%
S&P 500 (^GSPC)
70.10%

5-Year Return

MBX
87.09%
S&P 500 (^GSPC)
80.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -23.58M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-20M
-15M
-10M
-5M
0

Analyst Insights

View More

Analyst Price Targets

20.00 Low
69.09 Average
43.03 Current
91.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/12/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 66 -> 70

Statistics

View More

Valuation Measures

Annual
As of 6/18/2026
  • Market Cap

    2.05B

  • Enterprise Value

    1.61B

  • Trailing P/E

    3.88

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.68

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -17.68%

  • Return on Equity (ttm)

    -25.73%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -86.61M

  • Diluted EPS (ttm)

    -2.17

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    439.98M

  • Total Debt/Equity (mrq)

    0.13%

  • Levered Free Cash Flow (ttm)

    -52.45M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

43.03 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: